NCIt definition : An orally available small molecule dual inhibitor targeting human vascular endothelial
growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs)
with antiangiogenic and antineoplastic activities. Vorolanib inhibits all isoforms
of VEGFR and PDGFR, which may result in the inhibition of tumor angiogenesis and tumor
cell proliferation, and the induction of tumor cell death. Both VEGFRs and PDGFRs
are receptor tyrosine kinases that may be upregulated in various tumor cell types.
Vorolanib has been shown to reduce tissue toxicity by 95 percent compared with first-generation
kinase inhibitors.;
UNII : YP8G3I74EL;
InChIKey : KMIOJWCYOHBUJS-HAKPAVFJSA-N;
CAS number : 1013920-15-4; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1013920-15-4
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;